Quick facts
- An eye drop that makes a therapeutic claim is a drug in both countries, not a device. That part does not differ.
- United States: ophthalmic drug products for over-the-counter human use are governed by a monograph. 21 CFR 349.12 lists the permitted demulcents for a tear-replacement claim, and 21 CFR 349.14 lists the emollients.
- Canada: there is no monograph route in the same form. Section C.01.014(1) of the Food and Drug Regulations states that no manufacturer shall sell a drug in dosage form unless a drug identification number has been assigned for that drug.
- The device side of the same complaint has its own entries in the United States: an eyelid thermal pulsation system and an intense pulsed light device for managing dry eye are both Class II, and the second is a prescription device.
- For a buyer, the practical split is between what a clinic may stock as a general product and what may only be supplied against a prescription and a number.
- 🔴 Nothing in this article is a recommendation to use or supply any particular drop. It describes the regulatory route only.
An eye drop is the least expensive-looking item in an eye clinic and the most heavily regulated. The same 10 mL bottle can be an over-the-counter drug, a prescription drug, or a device depending on the words on the label, and the route differs between Canada and the United States even when the claim is identical. This article sets out which route applies, why the monograph matters, and where the device entries sit relative to the drop.
What decides whether a drop is a drug or a device?
The claim decides it. A product that is sold to treat, mitigate or prevent a condition is a drug. A product that is sold to do something mechanical — to hold moisture against the surface of the eye, to protect it, to measure it — can be a device.
The interesting part is that the same clinical complaint, dry eye, is served by both categories in the United States, and they are regulated completely separately:
| Item | Canada | United States |
|---|---|---|
| Tear-replacement drop with a demulcent claim | Drug; drug identification number required before sale | Drug; over-the-counter monograph route available |
| Prescription ophthalmic product | Drug; prescription status set in the product authorisation | Drug; prescription status set in the application |
| Powered eyelid heat and pressure system | Active therapeutic device, Rule 9(1) Class II | 21 CFR 886.5200, Class II with special controls |
| Intense pulsed light for dry eye | Active therapeutic device, Rule 9(1) Class II | 21 CFR 886.5201, Class II and prescription |
| Non-implantable tear stimulator | Rule 12 Class I unless it withdraws or administers energy | 21 CFR 886.5305, Class II with special controls |
| Nasolacrimal compression device | Rule 7(1) Class I | 21 CFR 886.5838, Class I, prescription device |
Read the table down the middle column and the Canadian logic is visible: the class follows energy and purpose, not marketing category. An active therapeutic device that administers or withdraws energy to or from the body is Class II under Rule 9(1) of Schedule 1 to the Medical Devices Regulations. A passive item that only sits against the eye is reached by Rule 7(1) and lands in Class I, unless it is intended to be connected to a Class II or higher active device, which pulls it into Class II under Rule 7(2)(b).
Read the right-hand column and the American logic is visible: the category is whatever section of Title 21 the device was filed under, and the class is stated in that section.
The label is where the route is actually chosen, so it is worth reading the words on the bottle against the rule that follows them:
| Words on the label | Canada | United States |
|---|---|---|
| Lubricates and rewets the eye, demulcent ingredients | Drug; a drug identification number is required before sale | Drug; monograph route where ingredient and concentration match the monograph |
| Relieves dryness or irritation | Drug | Drug |
| Washes away debris mechanically, with no therapeutic claim | Can be a device; Rule 7(1) Class I | Can be a device; general hospital and personal use sections apply |
| Treats or prevents an infection | Prescription drug | Prescription drug |
| Ingredient or strength outside the permitted lists | Product-specific authorisation | Product-specific application |
Does the United States really let a drop be sold without an application?
Not without a rule, but without a product-specific application. An over-the-counter ophthalmic drug can be marketed under 21 CFR part 349, the monograph for ophthalmic drug products for over-the-counter human use. A monograph is a rule that states which active ingredients are permitted for a stated claim, at what concentration, and what the label must say. A product that matches the monograph does not need an approved application of its own.
Two details decide whether a product really matches:
- The ingredient and the concentration. 21 CFR 349.12 is the demulcent list and 21 CFR 349.14 is the emollient list. A formulation outside those lists is not a monograph product.
- The label. 21 CFR 349.50 governs the labelling of ophthalmic drug products. A claim that does not match the monograph indication moves the product out of the monograph.
Any claim that goes beyond the monograph, and any new active ingredient, moves the product to a product-specific application. That is the boundary, and it is a boundary on claims rather than on chemistry.
What changes in Canada?
Canada has no monograph that a manufacturer can self-certify against in the same way. The Food and Drug Regulations set the mechanical requirement: section C.01.014(1) prohibits a manufacturer from selling a drug in dosage form unless a drug identification number has been assigned for that drug and the assignment has not been cancelled. An application under section C.01.014.1 supplies the manufacturer name, the pharmaceutical form, the recommended route of administration and the other particulars the section requires.
The practical consequence for a clinic is narrow but real: a Canadian clinic cannot substitute a United States over-the-counter ophthalmic product that trades on a monograph, because the Canadian route runs through a number rather than through a monograph.
- Stocking. A product sold in Canada must be able to show its Canadian authorisation.
- Labelling. French and English labelling obligations attach to the Canadian market, and the product authorisation is tied to the labelled claim.
- Repackaging. Splitting a drug product into smaller units changes the labelling and the record, and it is the step most often taken without thinking.
Where do the device entries sit relative to the drop?
They sit beside the drop, not in place of it, and they are a good illustration of how far the device route can reach into a complaint that is usually treated as drug territory.
In the United States the dry-eye device shelf now includes an eyelid thermal pulsation system, classified Class II with special controls, and an intense pulsed light device for managing dry eye, also Class II with special controls and described in the section as a prescription device. An electromechanical tear stimulator, a non-implantable device intended to increase tear production by mechanical stimulation, is Class II. A nasolacrimal compression device, which applies pressure to reduce outflow through the nasolacrimal ducts, is Class I and is described as a prescription device.
Canada reaches these devices by rule rather than by entry. A powered heat-and-pressure unit administered to the eyelid is an active therapeutic device under Rule 9(1) and is Class II. A passive device that merely rests against the skin around the eye is non-invasive, does not contact injured skin, and is Class I under Rule 7(1). Neither outcome depends on whether the maker calls the product a device; it depends on what the device does with energy.
What should a clinic be able to show for an ophthalmic product?
Four records cover almost every question that comes up.
- The Canadian authorisation or the United States basis. For a drug, the number or the monograph basis; for a device, the class and the route.
- The labelled claim. The claim is what puts the product in one category rather than another, so the label belongs in the file.
- The physical separation in storage. Prescription and non-prescription ophthalmic products should not share an unlabelled drawer, because the whole point of the split is that one may be handed out and the other may not.
- The single-use discipline. A multi-dose bottle that is used for more than one patient is a cross-contamination question that the drug route does not answer for you.
Which consumables does the surrounding room use?
The examination room around any ophthalmic product restocks table paper, swabs, gloves, dressing pads and hand-hygiene supplies in the same cycle. For clinics buying at case level, the wholesale ordering page sets out account and case terms, and the B2B wholesale collection lists the lines held for institutional buyers. The examination table paper roll covers the lane, the wall-mounted eye wash station covers the emergency side, and clinics that also run an in-house sterilizer can start with the biological indicator 5-pack trial and the sterilization monitoring collection.
Sources
- 21 CFR part 349, ophthalmic drug products for over-the-counter human use
- 21 CFR 349.12, ophthalmic demulcents
- 21 CFR 349.14, ophthalmic emollients
- 21 CFR 349.50, labeling of ophthalmic drug products
- 21 CFR 886.5200, eyelid thermal pulsation system
- 21 CFR 886.5201, intense pulsed light device for managing dry eye
- 21 CFR 886.5305, electromechanical tear stimulator
- 21 CFR 886.5838, nasolacrimal compression device
- 21 CFR 886.9, limitations of exemptions
- Food and Drug Regulations, C.R.C., c. 870, full text
- Medical Devices Regulations, SOR/98-282, full text and Schedule 1
- Health Canada, medical devices
- Food and Drug Regulations, C.R.C., c. 870, section C.01.014
- openFDA device classification API
- College of Optometrists of Ontario, standards of practice
- Canadian Association of Optometrists, eye health library
- National Eye Institute, eye health information
- American Academy of Ophthalmology, eye health
- ISO 15004-1:2020, ophthalmic instruments, general requirements
- World Health Organization, blindness and visual impairment
Related product: Related product: USB heated eye mask with three temperature settings (graphene heating element)
Related reading
- Contact Lens Rewetting Drops in Canada vs the US: Which Product Rules Apply
- Contact Lens Solutions in Canada vs the US: Which Rules Apply
- Eye Wash Solution in Canada vs the US: Which Flushing Fluid Rules Apply
- US Heated Eye Masks: Graphene Warm Compress for Tired Eyes
CliniEco Medical supplies eye care, laboratory and clinic consumables of the kind described in this article. MDEL #35334. This article is written for clinic, procurement and infection-control professionals and is not clinical guidance; this article does not recommend or promote any ophthalmic drug, and prescribing decisions belong to the licensed prescriber.
Frequently Asked Questions
Is an eye drop a drug or a device?
It depends on the claim. A drop that is sold to treat, mitigate or prevent a condition is a drug in both Canada and the United States. A product whose only function is mechanical, such as holding moisture against the surface of the eye or protecting it, can be a device.
Can a United States over-the-counter eye drop be sold in Canada?
Not on the basis of the United States monograph. Canada requires a drug identification number to be assigned before a drug in dosage form may be sold by a manufacturer, under section C.01.014(1) of the Food and Drug Regulations.
What is an over-the-counter monograph?
It is a rule that lists the permitted active ingredients and concentrations for a stated over-the-counter claim, together with the labelling requirements. For ophthalmic products the monograph sits in 21 CFR part 349; the demulcents are listed in section 349.12 and the emollients in section 349.14.
Does dry eye treatment count as a device in the United States?
Only where the product is a device. The FDA has device entries for a powered eyelid thermal pulsation system and for an intense pulsed light device for managing dry eye, both Class II with special controls, and the second is described in its section as a prescription device. A drop is still a drug.
How is a powered dry eye device classified in Canada?
As an active therapeutic device. Rule 9(1) of Schedule 1 to the Medical Devices Regulations classifies an active therapeutic device that administers or withdraws energy to or from the body as Class II. A passive item that only rests against the skin around the eye is reached by Rule 7(1) and is Class I.
What records should a clinic keep for ophthalmic products?
The Canadian authorisation or the United States basis for the product, the labelled claim, the storage separation between prescription and non-prescription stock, and the single-use discipline applied to multi-dose bottles. The labelled claim is the item that usually decides which category the product falls into.
0 comments